Study Title
Study Details
Description:
The goal of this clinical trial is to evaluate the safety and tolerability of increasing doses of [177Lu]Lu-AKIR001, both in relation to tolerable activity of lutetium-177 and the absorbed protein mass dose of AKIR-001 in patients with irresectable or metastatic CD44v6-expressing solid malignancies for whom no reasonable systemic treatment options are be available.
Sponsor:
Karolinska University HospitalGovernment Study Link:
NCT06639191 - Click here to see study onClinicalTrials.gov
Drug Details